| Literature DB >> 29993339 |
Shanhu Qiu1, Xue Cai2, Xuyi Wang2, Can He3, Martina Zügel4, Jürgen Michael Steinacker4, Uwe Schumann4.
Abstract
BACKGROUND: Although step counters are popularly employed for physical rehabilitation in chronic obstructive pulmonary disease (COPD) patients, their effectiveness is inconsistent and even questioned. This meta-analysis aimed to investigate whether step counter use increases physical activity or improves exercise capacity in COPD patients.Entities:
Keywords: chronic obstructive pulmonary disease; exercise capacity; physical activity; step counter
Mesh:
Year: 2018 PMID: 29993339 PMCID: PMC6048621 DOI: 10.1177/1753466618787386
Source DB: PubMed Journal: Ther Adv Respir Dis ISSN: 1753-4658 Impact factor: 4.031
Figure 1.Flow diagram of literature search and selection processes.
COPD, chronic obstructive pulmonary disease; RCT, randomized controlled trial.
aTwo articles enrolled the same groups of patients but with different follow-up periods,[18,19] which were treated as 1 RCT,[19] while one article provided three different comparisons,[13] resulting in 3 separate RCTs, 15 RCTs in total were therefore included.
Characteristics of included studies in the meta-analysis.
| Source | Descriptions of intervention and control groups | Duration (weeks) | Telehealth[ | Disease severity[ | PA assessment |
|---|---|---|---|---|---|
|
| |||||
| Altenburg | 12 | No | 78 | steps/day; pedometer | |
| Altenburg | 12 | No | 58 | steps/day; pedometer | |
| Demeyer | 12 | Yes | 56 | steps/day; accelerometer | |
| Hornikx | 4 | Yes | 42 | steps/day; accelerometer | |
| Hospes | 12 | No | 64.7 | steps/day; pedometer | |
| Mendoza | 12 | No | 66.1 | steps/day; accelerometer | |
| Moy | 52 | Yes | NS | steps/day; accelerometer | |
| Tabak | 4 | Yes | 52.6 | steps/day; pedometer | |
| Vorrink | 24 | No | 56 | steps/day (weekday); accelerometer | |
|
| |||||
| Altenburg | 12 | No | 43 | steps/day; pedometer | |
| Cruz and colleagues[ | 12 | No | 67.1 | steps/day; accelerometer | |
| de Blok | 9 | No | 48 | steps/day; pedometer | |
| Kawagoshi | 52 | No | 56.6 | walking time; accelerometer | |
| Nolan | 8 | No | 50.5 | steps/day; accelerometer | |
|
| 8 | Yes | 51 | steps/day; accelerometer | |
NS, not specified; PA, physical activity; PR, pulmonary rehabilitation.
It included components like telephone calls, text messages, or internet applications.
It was assessed by baseline mean values of forced expiratory volume in 1s, %pred in both groups.
This study enrolled patients from general practices.
This study enrolled in outpatient hospital clinics.
This study enrolled patients from a PR center (i.e. receiving PR programs).
Figure 2.Effect sizes of step counter use on physical activity in patients with chronic obstructive pulmonary disease.
CI, confidence interval; PR, pulmonary rehabilitation; SD, standard deviation; SMD, standard mean difference; UC, usual care.
aThis study enrolled patients from general practice.
bThis study enrolled in outpatient hospital clinics.
cThis study enrolled patients from a pulmonary rehabilitation center (i.e. receiving pulmonary rehabilitation programs).
dData were collected using the methods described in Supplementary Table S2.
Subgroup analyses on physical activity outcomes.
| Subgroups | Overall analysis | Step counter use | Step counter use + PR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Effect size[ | I2,% | No. | Effect size[ | I2,% | No. | Effect size[ | I2,% | ||||
| SMD | 95% CI | SMD | 95% CI | SMD | 95% CI | |||||||
| Diary use | ||||||||||||
| With | 9 | 0.62 | 0.33–0.91 | 67 | 5 | 0.68 | 0.39 to 0.97 | 45 | 4 | 0.65 | 0.05 to 1.25 | 77 |
| Without | 6 | 0.51 | 0.02 to 0.99 | 78 | 4 | 0.45 | −0.16 to 1.05 | 85 | 2 | 0.71 | 0.09 to 1.33 | 1 |
| Telehealth elements[ | ||||||||||||
| With | 5 | 0.39 | 0.07 to 0.71 | 59 | 4 | 0.38 | −0.02 to 0.78 | 69 | 1 | 0.38 | −0.14 to 0.91 | NA |
| Without | 10 | 0.72 | 0.32 to 1.12 | 81 | 5 | 0.73 | 0.09 to 1.36 | 88 | 5 | 0.73 | 0.15 to 1.31 | 71 |
| Step counter | ||||||||||||
| Pedometer | 6 | 0.72 | 0.22 to 1.22 | 64 | 4 | 0.79 | 0.04 to 1.54 | 78 | 2 | 0.60 | 0.04 to 1.15 | 1 |
| Accelerometer | 9 | 0.50 | 0.18 to 0.82 | 80 | 5 | 0.41 | 0.00 to 0.82 | 85 | 4 | 0.70 | 0.06 to 1.34 | 78 |
| Intervention duration | ||||||||||||
| <6 months | 12 | 0.67 | 0.38 to 0.97 | 71 | 7 | 0.72 | 0.34 to 1.10 | 71 | 5 | 0.63 | 0.11 to 1.14 | 69 |
| ⩾6 months | 3 | 0.15 | −0.12 to 0.42 | 31 | 2 | 0.08 | −0.13 to 0.29 | 1 | 1 | 0.77 | −0.02 to 1.56 | NA |
| Disease severity[ | ||||||||||||
| Moderate | 11 | 0.68 | 0.37 to 0.99 | 77 | 7 | 0.70 | 0.31 to 1.08 | 78 | 4 | 0.70 | 0.06 to 1.34 | 78 |
| Severe | 3 | 0.38 | −0.07 to 0.83 | 1 | 1 | −0.02 | −0.78 to 0.74 | NA | 2 | 0.60 | 0.04 to 1.15 | 1 |
| Data analysing | ||||||||||||
| ITT | 6 | 0.41 | 0.08 to 0.73 | 82 | 4 | 0.48 | 0.03 to 0.93 | 88 | 2 | 0.21 | −0.08 to 0.50 | 1 |
| Per-protocol | 9 | 0.76 | 0.32 to 1.20 | 67 | 5 | 0.63 | −0.02 to 1.28 | 76 | 4 | 0.94 | 0.35 to 1.54 | 50 |
CI, confidence interval; ITT, intention-to-treat; NA, not applicable; PR, pulmonary rehabilitation; SMD, standard mean difference.
Effect sizes were analyzed using a random-effects model.
It included components like telephone calls, text messages, or internet applications.
Disease severity was assessed based on mean values of forced expiratory volume in 1s, %pred, in both groups.
Disease severity was not clearly reported in the study by Moy and colleagues[19]
Figure 3.Effect sizes of step counter use on exercise capacity in patients with chronic obstructive pulmonary disease.
CI, confidence interval; PR, pulmonary rehabilitation; SD, standard deviation; SMD, standard mean difference; UC, usual care.
aThis study enrolled patients from general practice.
bThis study enrolled in outpatient hospital clinics.
cThis study enrolled patients from a pulmonary rehabilitation center (i.e. receiving pulmonary rehabilitation programs).
dData were collected using the methods described in Supplementary Table S2.
Subgroup analyses on exercise capacity outcomes.
| Subgroups | Overall analysis | Step counter use | Step counter use + PR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Effect size[ | I2,% | No. | Effect size[ | I2,% | No. | Effect size[ | I2,% | ||||
| SMD | 95% CI | SMD | 95% CI | SMD | 95% CI | |||||||
| Diary use | ||||||||||||
| With | 8 | 0.31 | 0.17 to 0.45 | 1 | 4 | 0.34 | 0.16 to 0.52 | 1 | 4 | 0.25 | −0.02 to 0.51 | 25 |
| Without | 5 | 0.43 | −0.03 to 0.89 | 56 | 3 | 0.25 | −0.21 to 0.71 | 48 | 2 | 0.87 | −0.28 to 2.03 | 66 |
| Telehealth elements[ | ||||||||||||
| With | 4 | 0.28 | 0.08 to 0.47 | 24 | 3 | 0.21 | 0.03 to 0.40 | 1 | 1 | 0.50 | 0.17 to 0.83 | NA |
| Without | 9 | 0.34 | 0.12 to 0.56 | 20 | 4 | 0.46 | 0.19 to 0.73 | 1 | 5 | 0.25 | −0.14 to 0.64 | 41 |
| Intervention duration | ||||||||||||
| <6 months | 11 | 0.34 | 0.19 to 0.50 | 14 | 6 | 0.35 | 0.18 to 0.52 | 1 | 5 | 0.31 | −0.05 to 0.67 | 54 |
| ⩾6 months | 2 | 0.10 | −0.21 to 0.41 | 1 | 1 | 0.05 | −0.29 to 0.39 | NA | 1 | 0.35 | −0.41 to 1.12 | NA |
| Disease severity[ | ||||||||||||
| Moderate | 10 | 0.31 | 0.18 to 0.44 | 1 | 6 | 0.30 | 0.15 to 0.46 | 1 | 4 | 0.33 | 0.11 to 0.55 | 1 |
| Severe | 3 | 0.37 | −0.49 to 1.24 | 70 | 1 | 0.04 | −0.72 to 0.80 | NA | 2 | 0.64 | −1.01 to 2.28 | 84 |
| Data analysing | ||||||||||||
| ITT | 5 | 0.29 | 0.14 to 0.44 | 10 | 3 | 0.40 | 0.06 to 0.73 | 1 | 2 | 0.35 | 0.03 to 0.66 | 41 |
| Per-protocol | 8 | 0.34 | 0.04 to 0.64 | 27 | 4 | 0.26 | 0.07 to 0.45 | 15 | 4 | 0.33 | −0.27 to 0.93 | 55 |
CI, confidence interval; ITT, intention-to-treat; NA, not applicable; PR, pulmonary rehabilitation; SMD, standard mean difference.
Effect sizes were analyzed using a random-effects model.
It included components like telephone calls, text messages, or internet applications.
Disease severity was assessed based on mean values of forced expiratory volume in 1 s, %pred, in both groups.